ALTEOGEN Inc. (196170.KQ)
KRW 286500.0
(-3.54%)
KRW 286500.0
(-3.54%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 53.56 Billion KRW | 35.02% |
| 2022 | 39.67 Billion KRW | -61.88% |
| 2021 | 104.07 Billion KRW | 104.13% |
| 2020 | 50.98 Billion KRW | 3455.94% |
| 2019 | 1.43 Billion KRW | 120.15% |
| 2018 | -7.11 Billion KRW | -36.07% |
| 2017 | -5.22 Billion KRW | 37.64% |
| 2016 | -8.38 Billion KRW | -18.48% |
| 2015 | -7.07 Billion KRW | 18.33% |
| 2014 | -8.66 Billion KRW | -958.99% |
| 2013 | 1 Billion KRW | 265.68% |
| 2012 | -608.95 Million KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 62.59 Billion KRW | 6.43% |
| 2024 Q1 | 58.81 Billion KRW | 9.79% |
| 2023 FY | 53.56 Billion KRW | 35.02% |
| 2023 Q4 | 53.56 Billion KRW | -12.35% |
| 2023 Q1 | 38.42 Billion KRW | -3.14% |
| 2023 Q3 | 61.11 Billion KRW | 7.96% |
| 2023 Q2 | 56.61 Billion KRW | 47.33% |
| 2022 Q4 | 39.67 Billion KRW | -45.35% |
| 2022 Q2 | 63.03 Billion KRW | 7.74% |
| 2022 FY | 39.67 Billion KRW | -61.88% |
| 2022 Q1 | 58.51 Billion KRW | -43.78% |
| 2022 Q3 | 72.59 Billion KRW | 15.16% |
| 2021 Q4 | 104.07 Billion KRW | 108.7% |
| 2021 FY | 104.07 Billion KRW | 104.13% |
| 2021 Q2 | 56.54 Billion KRW | 1051.37% |
| 2021 Q3 | 49.86 Billion KRW | -11.82% |
| 2021 Q1 | 4.91 Billion KRW | 113.99% |
| 2020 Q4 | -35.1 Billion KRW | -1393.83% |
| 2020 Q3 | -2.34 Billion KRW | 8.38% |
| 2020 Q1 | -6.84 Billion KRW | -2515.46% |
| 2020 Q2 | -2.56 Billion KRW | 62.53% |
| 2020 FY | 50.98 Billion KRW | 3455.94% |
| 2019 Q2 | -2.37 Billion KRW | 63.63% |
| 2019 Q3 | -5.97 Billion KRW | -151.41% |
| 2019 FY | 1.43 Billion KRW | 120.15% |
| 2019 Q1 | -6.53 Billion KRW | 8.15% |
| 2019 Q4 | -261.67 Million KRW | 95.62% |
| 2018 Q1 | -5.2 Billion KRW | 0.45% |
| 2018 Q4 | -7.11 Billion KRW | 12.72% |
| 2018 FY | -7.11 Billion KRW | -36.07% |
| 2018 Q2 | -16.72 Billion KRW | -221.33% |
| 2018 Q3 | -8.15 Billion KRW | 51.26% |
| 2017 Q1 | -7.87 Billion KRW | 6.08% |
| 2017 FY | -5.22 Billion KRW | 37.64% |
| 2017 Q3 | -5.08 Billion KRW | 27.53% |
| 2017 Q2 | -7.01 Billion KRW | 10.91% |
| 2017 Q4 | -5.22 Billion KRW | -2.84% |
| 2016 Q2 | -7.17 Billion KRW | 2.7% |
| 2016 Q3 | -11.42 Billion KRW | -59.26% |
| 2016 Q4 | -8.38 Billion KRW | 26.58% |
| 2016 FY | -8.38 Billion KRW | -18.48% |
| 2016 Q1 | -7.37 Billion KRW | -4.13% |
| 2015 FY | -7.07 Billion KRW | 18.33% |
| 2015 Q2 | -5.6 Billion KRW | 24.96% |
| 2015 Q1 | -7.46 Billion KRW | 13.87% |
| 2015 Q3 | -4.97 Billion KRW | 11.1% |
| 2015 Q4 | -7.07 Billion KRW | -42.14% |
| 2014 Q4 | -8.66 Billion KRW | 0.0% |
| 2014 FY | -8.66 Billion KRW | -958.99% |
| 2014 Q2 | -4.27 Billion KRW | -160.92% |
| 2014 Q1 | 7.01 Billion KRW | 595.62% |
| 2013 Q3 | 1 Billion KRW | 0.0% |
| 2013 Q1 | 4.26 Billion KRW | 0.0% |
| 2013 Q4 | 1 Billion KRW | 0.0% |
| 2013 FY | 1 Billion KRW | 265.68% |
| 2012 FY | -608.95 Million KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Co., Ltd. | -46.18 Billion KRW | 215.994% |
| iNtRON Biotechnology, Inc. | -40.58 Billion KRW | 231.995% |
| BINEX Co., Ltd. | 45.34 Billion KRW | -18.132% |
| Bioneer Corporation | -3.9 Billion KRW | 1470.852% |
| Anterogen.Co.,Ltd. | 8.35 Billion KRW | -541.42% |
| MEDIPOST Co., Ltd. | 14.81 Billion KRW | -261.61% |
| CrystalGenomics, Inc. | 8.99 Billion USD | -495.758% |
| Helixmith Co., Ltd | -24.42 Billion KRW | 319.317% |
| Chabiotech Co.,Ltd. | 388.94 Billion KRW | 86.227% |
| Medy-Tox Inc. | 49.58 Billion KRW | -8.038% |
| Peptron, Inc. | 4.86 Billion KRW | -1000.31% |
| Amicogen, Inc. | 125.26 Billion KRW | 57.234% |
| Genexine, Inc. | 61.39 Billion KRW | 12.746% |
| HLB Therapeutics Co.,Ltd. | -13.68 Billion KRW | 491.4% |
| LegoChem Biosciences, Inc. | -56.05 Billion KRW | 195.569% |
| PharmaResearch Co., Ltd. | -32.93 Billion KRW | 262.637% |
| SillaJen, Inc. | -13.89 Billion KRW | 485.629% |
| JETEMA, Co., Ltd. | 84.27 Billion KRW | 36.438% |
| OliX Pharmaceuticals,Inc | 27.37 Billion KRW | -95.691% |
| Genomictree Inc. | -43.43 Billion KRW | 223.333% |
| MedPacto, Inc. | -64 Billion KRW | 183.702% |
| D&D Pharmatech | -7.5 Billion KRW | 813.524% |
| EASY BIO,Inc. | 53.21 Billion KRW | -0.676% |
| GI Innovation, Inc. | -4.82 Billion KRW | 1210.833% |